Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1952 1
1964 1
1977 1
1981 2
1983 1
1985 2
1986 2
1988 1
1990 2
1992 1
1993 4
1994 2
1995 3
1997 1
1998 5
1999 3
2000 2
2001 4
2002 4
2003 9
2004 4
2005 10
2006 9
2007 10
2008 20
2009 17
2010 37
2011 34
2012 33
2013 37
2014 57
2015 61
2016 42
2017 37
2018 42
2019 52
2020 48
2021 62
2022 58
2023 14

Text availability

Article attribute

Article type

Publication date

Search Results

645 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, Lee DH, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ. Cho BC, et al. Among authors: lee gw. J Thorac Oncol. 2022 Apr;17(4):558-567. doi: 10.1016/j.jtho.2021.11.025. Epub 2021 Dec 24. J Thorac Oncol. 2022. PMID: 34958928 Free article. Clinical Trial.
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC. Ahn MJ, et al. Among authors: lee gw. Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3. Lancet Oncol. 2019. PMID: 31587882 Clinical Trial.
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC. Senan S, et al. Among authors: lee gw. Clin Lung Cancer. 2020 Mar;21(2):e84-e88. doi: 10.1016/j.cllc.2019.12.006. Epub 2019 Dec 28. Clin Lung Cancer. 2020. PMID: 31948903 Free article. Clinical Trial.
Diagnostic Technology for Spine Pathology.
Kim GU, Park WT, Chang MC, Lee GW. Kim GU, et al. Among authors: lee gw. Asian Spine J. 2022 Oct;16(5):764-775. doi: 10.31616/asj.2022.0374. Epub 2022 Oct 21. Asian Spine J. 2022. PMID: 36266250 Free PMC article.
MicroRNAs, genomic instability and cancer.
Vincent K, Pichler M, Lee GW, Ling H. Vincent K, et al. Among authors: lee gw. Int J Mol Sci. 2014 Aug 20;15(8):14475-91. doi: 10.3390/ijms150814475. Int J Mol Sci. 2014. PMID: 25141103 Free PMC article. Review.
645 results